Immunogenic Composition and Peptide Sequences for Prevention and Treatment of an Hsv Condition

1 ) Immunogenic composition comprising at least one Herpes Simplex Virus type 1 (HSV-1) and/or type 2 (HSV-2) epitope containing peptide from glycoprotein D (gD) and/or glycoprotein B (gB), a pharmaceutical carrier and/or a human compatible adjuvant, wherein said epitope containing peptide having the capacity to bind on at least three alleles of humans HLA class II molecules having a frequency superior to 5% in a Caucasian population, with a binding activity less or equal to 1000 nanomolar.

2 ) Immunogenic composition according to claim 1 , wherein said epitope containing peptide having the capacity to bind on at least five alleles of humans HLA class II molecules having a frequency superior to 5% in a Caucasian population, with a binding activity less or equal to 800 nanomolar.

3 ) Immunogenic composition according to claim 1 , wherein said epitope containing peptide is selected from the group of peptide sequences consisting of SEQ ID N o 1 to SEQ ID N o 12, SEQ ID N o 14 to SEQ ID N o 25, SEQ ID N o 28 to SEQ ID N o 39, and SEQ ID N o 41 to SEQ ID N o 52, or fragments thereof.

4 ) Immunogenic composition according to claims 1 to 3 , wherein it comprises a combination of 2 to 8 epitope containing peptides.

5 ) Immunogenic composition according to claim 4 , wherein it comprises a combination of 3 to 7 epitope containing peptides from gD HSV-1 selected from the group of peptide sequences consisting of SEQ ID N o 2, SEQ ID N o 5, SEQ ID N o 7, SEQ ID N o 8, SEQ ID N o 10, SEQ ID N o 11 and SEQ ID N o 12, preferably a combination of 3 to 5 epitope containing peptides selected from the group of peptide sequences consisting of SEQ ID N o 2, SEQ ID N o 7, SEQ ID N o 8, SEQ ID N o 10, and SEQ ID N o 11, and more preferably a combination of 4 epitope containing peptide selected from the group of peptide sequences consisting of SEQ ID N o 2, SEQ ID N o 7, SEQ ID N o 8 and SEQ ID N o 10, and/or the corresponding gD HSV-2 epitope containing peptides, or combinations of said gD HSV-1 and gD HSV-2 epitope containing peptides.

6 ) Immunogenic composition according to claim 5 , wherein the corresponding HSV-2 epitope containing peptides present an homology of the peptide sequence with the HSV-1 epitope containing peptide of at least 70%, preferably at least 80%, more preferably at least 90%.

7 ) Immunogenic composition according to claim 1 , wherein the epitope containing peptide is in an amount from about 50 μg to about 5 mg.

8 ) Immunogenic composition according to claim 1 , wherein the human compatible adjuvant is the Montanide ISA 720, in an amount from about 15 μl to about 25 μl.

9 ) Immunogenic composition according to claim 1 , wherein the pharmaceutical carrier is selected from the group consisting of water, alcohol, natural or hardened oil, natural or hardened wax, calcium carbonate, sodium carbonate, calcium phosphate, kaolin, talc, lactose, lipid tail and combination thereof, in an amount of about 10 μl to about 100 μl.

10 ) Immunogenic composition according to claim 1 , further comprising an additional component selected from the group consisting of a vehicle, an additive, an excipient, a pharmaceutical adjunct, a therapeutic compound or agent useful in the treatment of HSV and combinations thereof.

11 ) Immunogenic composition according to claim 1 , wherein the composition is formulated to be administered by a technique selected from the group consisting of systemic injection, mucosal administration, topical administration, spray, drop, aerosol, gel and sweet formulation, and particularly is formulated to be administered by systemic injection, more particularly by subcutaneous injection.

12 ) Immunogenic composition according to claim 1 for use as a medicament.

13 ) Use of an immunogenic composition according to claim 1 for the manufacture of a medicament for prevention or treatment of a condition selected from the group consisting of HSV-1 primary infections, HSV-1 recurrences, HSV-2 primary infection, HSV-2 recurrences, cold sores, genital lesions, corneal blindness, and encephalitis, a condition in which a stimulation of IL-2 and IFN-γ is desirable and in which the induction of the Th-1 subset of T-cells is desirable.

14 ) HSV-1 or HSV-2 peptide sequence bearing at least one epitope, or fragment thereof, wherein said peptide sequence is selected from the group consisting of SEQ ID N o 1 to SEQ ID N o 11, SEQ ID N o 14 to SEQ ID N o 52.

15 ) Use of peptide sequence according to claim 14 for the manufacture of a medicament for treating or preventing a condition related to HSV-1 and/or HSV-2, and of a diagnosis reagent.